|
End-of-day quote
Taipei Exchange
06/05/2024
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 27/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/25/12 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 168.32Cr 5.24Cr 4.54Cr 4.26Cr 3.88Cr 7.31Cr 500.14Cr 7.42Cr 50Cr 20Cr 250.36Cr 20Cr 19Cr 835.16Cr | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 197.21Cr 6.14Cr 5.32Cr 4.99Cr 4.55Cr 8.56Cr 585.98Cr 8.7Cr 59Cr 23Cr 293.33Cr 23Cr 23Cr 978.51Cr | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 199.22 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 11/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 01/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Yun Fan
BRD | Director/Board Member | - | 30/06/2020 |
Yan Ning Kuo
BRD | Director/Board Member | - | 30/06/2020 |
Yao Hui Wei
BRD | Director/Board Member | - | 30/06/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -57.57% | 5.24Cr | |
| -0.92% | +1.43% | +83.05% | +128.86% | 1,07800Cr | |
| +0.47% | +1.98% | +50.26% | +50.75% | 63TCr | |
| +0.83% | +2.85% | +24.49% | +64.82% | 44TCr | |
| -1.28% | -2.45% | +43.26% | +35.28% | 36TCr | |
| -0.95% | -2.59% | +24.50% | +34.98% | 29TCr | |
| -1.44% | -2.74% | -0.14% | +4.10% | 25TCr | |
| +0.40% | +3.21% | +44.42% | +59.17% | 23TCr | |
| +1.41% | -0.84% | -6.76% | -51.15% | 20TCr | |
| +1.67% | +5.56% | +14.98% | +72.68% | 17TCr | |
| Average | +0.20% | +1.73% | +27.81% | +34.19% | 36.44TCr | |
| Weighted average by Cap. | -0.20% | +1.30% | +45.50% | +65.52% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 54Cr 1.68Cr 1.45Cr 1.36Cr 1.24Cr 2.34Cr 160.1Cr 2.38Cr 16Cr 6.27Cr 80Cr 6.3Cr 6.16Cr 267.35Cr | 51Cr 1.6Cr 1.39Cr 1.3Cr 1.19Cr 2.23Cr 152.86Cr 2.27Cr 15Cr 5.98Cr 77Cr 6.01Cr 5.88Cr 255.25Cr |
| Net income | -17Cr -54.33L -47.1L -44.15L -40.25L -75.74L -52Cr -76.96L -5.2Cr -2.03Cr -26Cr -2.04Cr -2Cr -87Cr | -30Cr -92.24L -79.96L -74.95L -68.34L -1.29Cr -88Cr -1.31Cr -8.83Cr -3.45Cr -44Cr -3.46Cr -3.39Cr -147.01Cr |
| Net Debt | 25Cr 76.7L 66.48L 62.32L 56.82L 1.07Cr 73Cr 1.09Cr 7.34Cr 2.86Cr 37Cr 2.88Cr 2.82Cr 122.23Cr | 29Cr 89.94L 77.96L 73.08L 66.64L 1.25Cr 86Cr 1.27Cr 8.61Cr 3.36Cr 43Cr 3.38Cr 3.3Cr 143.34Cr |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
